Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

11 papers

Ayahuasca for Addiction

Based on 11 papers

Research on ayahuasca for addiction is small but growing. Reviews and lab studies say the brew’s main ingredient (DMT) acts on brain serotonin systems and can boost the brain’s ability to rewire itself. This gives a scientific reason why ayahuasca might help people change long‑standing habits, but clinical trials specifically testing ayahuasca for addiction are limited and early. People who study psychedelic therapies agree that the drug itself is only part of the story. How a person is prepared, the setting, and follow‑up therapy matter a lot. There are also safety and fairness concerns. Some related drugs (like ibogaine) showed help for addiction but also caused serious heart and brain risks. Many studies are small, and people of color were often left out, so we cannot be sure the results apply to everyone.

Key findings

  • Some reviews say psychedelics, including DMT in ayahuasca, show promise for treating substance use problems, but the evidence is still early and not definitive. 15059 15058 15082
  • Ayahuasca’s active chemical, DMT, mainly affects serotonin receptors and lab studies show it can help the brain form new connections (called neuroplasticity). This may be one reason it could help break old habits. 15082 15050 15091
  • Clinical research specifically testing ayahuasca for addiction is limited. Most larger or later‑stage trials so far focus on other psychedelics like psilocybin or MDMA, not ayahuasca. 15082 15063 15085
  • People who have had psychedelic treatments often report deep personal insights, a changed sense of self, and stronger social connection. These kinds of changes are commonly described in studies and may relate to recovery from addiction. 15092 15059 15063
  • Non‑drug factors—such as preparation, the therapy during and after the session, the relationship with the therapist, and the setting—strongly shape outcomes. That means benefits seen in studies may depend on more than the brew itself. 15092 15063 15087
  • Some related plant medicines show both promise and real risks. For example, ibogaine has shown signs of helping addiction in some studies but has caused serious cardiac and neurological problems in other cases. 15085
  • Overall evidence strength is limited. Many studies are small, early‑stage, or not well controlled. Reviews warn that current results are promising but need larger, careful trials. 15091 15085 15058
  • People of color were underrepresented in psychedelic research up to 2017. This means we cannot assume study results apply equally across different ethnic or cultural groups. 15095
  • The growing psychedelic industry raises ethical and safety questions. Reviewers note it is not always clear how much benefit comes from the drug itself versus the therapeutic care around it, and commercial pressures add uncertainty. 15087 15085

Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature

Timothy I. Michaels, Jennifer Purdon, Alexis Collins, Monnica T. Williams
BMC Psychiatry Summary & key facts 2018 247 citations

The authors reviewed psychedelic-assisted psychotherapy studies published from 1993 to 2017 to see how many people of color took part. They found 18 studies with about 280 people. About 82% of participants were non-Hispanic White, while only small percentages were African American, Latino, Asian, indigenous, or mixed race. Because so…

Natural Compound Pharmacology Studies Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca LSD

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews Summary & key facts 2020 215 citations

This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…

Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Tryptophan and brain disorders Ayahuasca Ketamine

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, Eric Vermetten, Robert A. Schoevers
CNS Drugs Summary & key facts 2020 207 citations

Researchers collected and read 15 studies where patients described their own experiences with psychedelic treatments for mental disorders. These studies looked at about 180 patient accounts across different drugs and different illnesses. Even though the drugs and treatment settings were very different, many patients described similar helpful processes, such as…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Henry Lowe, Ngeh J. Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon, et al.
Molecules Summary & key facts 2022 52 citations

This paper is a review of research about psychedelic drugs and whether they could help with mood and anxiety problems. It explains that these drugs were used for thousands of years in some cultures, then were banned in the 1960s which slowed scientific study. The authors describe a new wave…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca LSD

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry

Jacob S. Aday, Brian S. Barnett, Dan Grossman, Kevin S. Murnane, Charles D. Nichols, Peter S. Hendricks
Psychedelic Medicine Summary & key facts 2023 49 citations

This article is a broad review of the new psychedelic industry. The authors look at how psychedelic drugs and clinics moved from decades-old research into a fast-growing business with hundreds of companies and big investment. They describe what companies are trying to sell, point out major scientific, legal, and ethical…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

The Emerging Field of Psychedelic Psychotherapy

Gregory Barber, Scott T. Aaronson
Current Psychiatry Reports Summary & key facts 2022 48 citations

This review looks at recent research where drugs like MDMA and psilocybin are given inside carefully run therapy programs. People get hours of preparation, one or more drug sessions, and several follow-up therapy sessions to help make sense of the experience. Trials so far show big improvements for some people…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ibogaine

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

Jennifer Mitchell, B. Anderson
Neuropsychopharmacology Summary & key facts 2023 44 citations

This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Serotonergic Psychedelics in Neural Plasticity

Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo, Ju Lu

This review explains that classical serotonergic psychedelics — drugs like psilocybin, DMT (in ayahuasca), LSD, and ibogaine — can change brain cells and connections in lab and animal studies. These drugs have been shown to help neurons grow new branches and form more synapses, which are the contact points where…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?

Nathan Emmerich, Bryce Humphries

This paper looks at whether trainee psychedelic therapists should be required to take psychedelic drugs so they can understand patients' experiences. The authors review the idea that first-person psychedelic trips give special knowledge, and they argue this benefit is not clearly unique or proven. They conclude that forcing trainees to…

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies Ayahuasca Ketamine

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Nataliya S. Vorobyeva, Alena A. Kozlova
Frontiers in Pharmacology Summary & key facts 2022 14 citations

This paper reviews research on three naturally occurring psychedelics: psilocybin, ibogaine, and N,N-dimethyltryptamine (the active part of the brew ayahuasca). It explains that these drugs work on the brain's serotonin system and summarizes growing studies that suggest they might help with problems like post-traumatic stress disorder, major depression, anxiety, and…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine

Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind

Alice Melani, Giorgia Papini, Marco Bonaso, Letizia Biso, Shivakumar Kolachalam, Nicola Luigi Bragazzi, et al.
Biomedicines Summary & key facts 2026 0 citations

This paper reviews research on ayahuasca and its main ingredient, DMT, and how they might help with mental health. Ayahuasca is a plant brew that makes DMT work when you drink it because it also contains chemicals that stop the body from breaking DMT down. Lab studies and a small…

Alkaloids: synthesis and pharmacology Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies Ayahuasca MDMA
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.